Design a pediatric febrile infant pathway: risk stratification, tests, LP criteria,…
- User
Design a pediatric febrile infant pathway: risk stratification, tests, LP criteria, empiric therapy, and safety net.
- Assistant
Pediatric Febrile Infant Pathway (<90 Days Old)
This pathway is designed for well-appearing febrile infants (rectal temp ≥38°C/100.4°F) presenting to the ED or outpatient setting. It is based on evidence-based guidelines including the 2021 AAP Clinical Practice Guideline for Febrile Infants 8-60 Days, Rochester/Philadelphia criteria modifications, PECARN low-risk criteria, and institutional protocols (e.g., CHOP, Seattle Children's Step-by-Step). Always consider local resistance patterns, consult ID/peds if unsure, and document shared decision-making with caregivers.
Key Principles:
- Prioritize ruling out serious bacterial infection (SBI: UTI, bacteremia, meningitis).
- Viral testing (e.g., RSV, influenza) may reduce antibiotic use if positive.
- HSV evaluation if <21 days, seizures, or concerning exam.
- Ill-appearing infants (e.g., hypotonia, poor perfusion, grunting): Full septic workup + empiric therapy + ADMIT IMMEDIATELY (bypass stratification).
1. Risk Stratification
Stratify by age, clinical appearance, and labs (after initial tests). Use table below:
Age Group Low-Risk Criteria (All Must Be Met) High-Risk Features (Triggers Full Eval/Admission) 0-7 days None—all high risk N/A—treat as high risk 8-28 days - Well-appearing- No focal bacterial source- Normal HR/RR/BP for age - Ill-appearing- Hypothermia- Focal source (e.g., omphalitis)- Abnormal exam (e.g., bulging fontanelle) 29-60 days (PECARN/Rochester-based) - Well-appearing- No focal source- WBC 5-15k/μL- Abs band <1.5k/μL (or UA normal)- CRP <40 mg/L- PCT <0.5 ng/mL (if available)- No UTI on UA - Ill-appearing- WBC >15k or <5k- Abs band ≥1.5k- CRP ≥40 mg/L- PCT ≥0.5 ng/mL- Abnormal UA (e.g., +nitrite/LE or >5 WBC/HPF) 61-90 days - Well-appearing- Meets 29-60d low-risk labs- Normal UA - Any high-risk from 29-60d- Recurrent fevers- Immunocompromise Notes:
- Low-risk probability of SBI: <1-2%.
- If any high-risk feature: Escalate to full evaluation.
2. Recommended Tests
Perform immediately based on age/risk (catheterize for UA/UCx; suprapubic if needed).
Test 0-28 Days 29-60 Days (Well-Appearing) 61-90 Days (Low-Risk) Blood Culture Yes Yes Yes (if low-risk eval) CBC w/ diff Yes Yes Optional (if high-risk) CRP (or PCT) Yes (guideline rec) Yes Optional UA + UCx Yes Yes Yes Viral Testing (nasal swab: RSV, Influenza, COVID) Consider (<28d or season) Yes Yes Chest X-ray If resp distress If resp distress If resp distress Other Blood gas if acidotic; HSV PCR if concern Stool studies if diarrhea - Rationale: UA/UCx detects 90% of SBIs in this age group. Biomarkers (CRP/PCT) improve specificity over WBC alone.
3. Lumbar Puncture (LP) Criteria
LP is mandatory if any of the following (full CSF: cell count, Gram stain, culture, enterovirus PCR ± HSV PCR):
Mandatory LP Consider LP (Shared Decision) Defer LP - Age 0-28 days- Ill-appearing- High-risk labs (e.g., WBC >15k, CRP >40)- Septic shock- HSV concern (e.g., seizures, rash, maternal h/o)- Antibiotics already given - Age 29-60 days, low-risk labs but positive blood culture pending- Focal neuro signs- Persistent fever >48h on abx - Age 29-90 days, low-risk labs + normal UA + negative viral test- Traumatic LP or failed attempt (treat empirically if high-risk)- Caregiver refusal (document risks) LP Tips: Use 22-25g spinal needle; ultrasound guidance if needed. Antibiotics before LP if delay anticipated.
CSF Interpretation:
- Pleocytosis (WBC >normal for age): Treat as bacterial until cultures final.
- Normal CSF: Discontinue abx if cultures negative at 24-36h.
4. Empiric Therapy
Start IV antibiotics after cultures (unless low-risk outpatient plan). Adjust for local patterns (e.g., E. coli resistance).
Age/Risk Group Regimen Duration/Notes 0-28 days (All) - Ampicillin 50 mg/kg IV q8-12h (covers Listeria/GBS) +- Gentamicin 5 mg/kg IV q24h (or Cefotaxime 50 mg/kg q8h if >7d) Admit; 36-48h pending cultures. Add Acyclovir 20 mg/kg IV q8h if HSV concern. 29-60 days, High-Risk Ceftriaxone 50 mg/kg IV q24h (+ Vancomycin if meningitis concern) Admit; 48h pending cultures. 29-60 days, Low-Risk Ceftriaxone 50 mg/kg IM/IV (single dose) 24-36h observation or home. 61-90 days, Low-Risk Ceftriaxone 50 mg/kg IM (if UA abnormal) or observation Home if normal labs/UA. UTI Confirmed Cephradine/cephalexin PO (adjust per sensitivities) 7-14 days. De-escalation: Stop abx at 24-36h if all cultures negative + low-risk.
5. Safety Net & Disposition
Discharge Criteria (Low-Risk Only)
- Meets low-risk criteria.
- Caregiver reliable, access to care, phone contact.
- Negative cultures at 24h (if observed).
- Tolerating PO, afebrile or improved.
Safety Net Instructions (Written + Verbal)
Return IMMEDIATELY if:
- Fever recurs/persists >24h.
- Lethargy, irritability, poor feeding, vomiting.
- Breathing difficulty, rash, seizures.
- Fewer wet diapers (<4-6/day), jaundice.
- Any new symptoms.
Follow-Up:
- Pediatrician/ED within 24h for culture results.
- Call lab results line daily until final (3-5 days).
- If cultures positive: Recall for IV/PO abx.
Observation Unit Plan (Preferred for Low-Risk 29-60d)
- Admit to 24-36h obs.
- Serial exams q4-6h.
- Stop abx if cultures negative.
Flowchart Summary (Text-Based)
Fever <90d → Triage: Ill? → YES: Full SWU + Abx + Admit ↓ NO (Well) Age? → 0-28d: Full SWU (incl LP) + Abx + Admit ↓ 29-60d: Labs + UA/UCx → Low-Risk? → YES: Ceftriaxone + 24h Obs/Home + Safety Net ↓ NO: Full SWU (LP if criteria) + Abx + Admit ↓ 61-90d: UA/UCx ± labs → Normal? → YES: Safety Net/Home ↓ NO: Abx ± Admit All: Viral test → + → Consider ↓ Abx Pending cultures: Safety Net + F/UQuality Metrics: Aim for <5% missed SBIs, LP success >90%, timely culture results. Audit locally. Consult peds/ID for exceptions (e.g., prematurity, AOM). This is a template—customize to your institution.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.